Philips launches Skylight, a cloud application for managing ultrasound fleets
In a press release published on November 18, 2026, Royal Philips unveiled Skylight Device Manager, a cloud application that brings together in a single place the data from connected ultrasound systems used by its hospital customers.
The group will demonstrate it at the RSNA 2026 congress in Chicago, alongside its other radiology innovations.
Locating and measuring the use of ultrasound systems and probes
Philips justifies this initiative by the constraints it observes among its customers: financial pressures, staff shortages and an increasingly complex management of ultrasound fleets. Because devices and probes frequently move between departments and facilities, healthcare systems may struggle to locate them and measure their use.
By cross-referencing probe and system data, the application is intended to identify underused equipment and compare utilization across sites. It also aims to prioritize potential incidents and inform decisions on maintenance, team organization, fleet deployment and investment.
“Healthcare systems are surrounded by data, but the value lies in transforming it into intelligence that enables faster technology decisions,” said Ajay Gannerkote, head of Philips’ ultrasound business. He presents Skylight as “a step” to help facilities “make the most of the technology they already have.”
Cited by the group as a customer, Dr. Michael S. Ruma (Perinatal Associates of New Mexico) manages “a fleet of 43 ultrasound systems spread across several sites.” In his view, bringing this information together in one place would offer “better visibility” across all of his equipment.
Limited rollout in the United States ahead of the extension to radiography
Skylight Device Manager is accessible through the Philips OneSpace platform, a single sign-on environment that centralizes the group’s digital applications. Philips plans to add other applications, training resources and software covering a wide range of imaging modalities.
The application is currently available only in the United States and supports only a selection of Philips ultrasound systems. The group intends to extend it to other modalities, with digital radiography (DXR) systems among the first expected, in order to give facilities an overview of their equipment across their entire organization.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
SectorDispositifs médicaux et optique›Dispositifs médicaux
Context
Period
Period: T3 2026
Key reported figures
Revenue: 4 393 millions d'euros
Quarterly revenue: 4 393 millions d'euros
Revenue growth: 2 %
Net income: 27 millions d'euros
Free cash flow: 384 millions d'euros
5 387 millions d'euros
Guidance from the release
« Our year-to-date results, together with our strong order book, give us confidence in delivering our full-year outlook and achieving our medium-term ambitions. » ; « Philips reiterates its full-year 2026 outlook »
Risks mentioned
Macro-economic and geopolitical changes including war in Ukraine and Middle East tensions, plus enacted and proposed tariffs and trade actions
Respironics-related legal proceedings and ongoing investigation by US State Attorneys General excluded from 2026 outlook
Phasing of Ultrasound sales and lower sales in China as previously communicated at Q2
Opportunities identified
Strong demand for latest AI-enabled innovations including new CT platforms Verida and Rembra, ultrasound system Alturion, and HealthSuite Imaging cloud solution
Accelerating innovation in image-guided therapy with EUR 50 million investment in AI, robotics and advanced imaging in Netherlands, plus EUR 150 million in private financing
Extended monitoring partnership with largest US health system through 2034 and expansion of Capsule platform, plus strategic partnerships in China and Latin America
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.